Objectif "T-cell engineering strategies for Cancer therapy, either Chimeric Antigen Receptors (CARs) or TCR transfer holds promise to revolutionize cancer treatment. There are, however, considerable barriers to be overcome to take this form of therapy to a format that can benefit all EU citizens with a wide range of common cancers. The aim of this consortium is to exploit advances in T-cell engineering to allow the full potential of CAR therapy to be unleashed.At present, CAR therapy requires a bespoke autologous therapeutic product for each patient. This greatly limits practicality, scalability and commercialisation. The development of a strategy for creation of universal engineered T-cells is the first key aim of this consortium. There is an increased appreciation of the immunological hostilities (CAR) T-cells face in the tumour microenvironment, and prevention of this local immune suppressive effect will likely be critical in permitting effective tumour control. The second main aim of this proposal is therefore to engineer CAR T-cells to be resistant to the hostile microenvironment. CAR T-cells can only be effective if they can access the tumour site. Exploiting the fact that neo-angiogenesis is a hallmark of neoplastic progression, the third aim of the consortium is to utilise endothelial cues of neo-angiogenesis to direct CAR T-cell migration and activity.The central technological theme of this consortium is the application of TALEN-mediated gene editing strategies alongside genetic modification with integrating vectors. Using this approach, we will implement a clinical study of “universal” CAR T-cells in refractory lymphoma. Further, this work will be complemented with highly focused development of T-cells which are resistant to hostile microenvironments and which can home to sites of neovascularization. The legacy this consortium wishes is commercialization of universal CAR therapy for a broad swathe of human cancers." Champ scientifique medical and health sciencesmedical biotechnologygenetic engineeringgene therapymedical and health sciencesclinical medicineoncology Programme(s) FP7-HEALTH - Specific Programme "Cooperation": Health Thème(s) HEALTH.2013.2.4.1-2 - Strengthening the cancer patient's immune system Appel à propositions FP7-HEALTH-2013-INNOVATION-1 Voir d’autres projets de cet appel Régime de financement CP-FP - Small or medium-scale focused research project Coordinateur UNIVERSITY COLLEGE LONDON Contribution de l’UE € 2 646 887,00 Adresse GOWER STREET WC1E 6BT LONDON Voir sur la carte Type d’activité Higher or Secondary Education Establishments Contact administratif Martin Scott (Mr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée Participants (5) Trier par ordre alphabétique Trier par contribution de l’UE Tout développer Tout réduire CELLECTICS THERAPEUTICS SAS Participation terminée France Contribution de l’UE Aucune donnée Adresse RUE DE LA CROIX DE JARRY 8 75013 PARIS Voir sur la carte Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Contact administratif Julianne Smith (Dr.) Liens Contacter l’organisation Opens in new window Coût total Aucune donnée CELLECTIS SA France Contribution de l’UE € 1 448 140,00 Adresse RUE JEAN ANTOINE DE BAIF 12 75013 PARIS Voir sur la carte Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Contact administratif Julianne Smith (Dr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée PHILOGEN SPA Italie Contribution de l’UE € 625 900,00 Adresse PIAZZA LA LIZZA 7 53100 Siena Voir sur la carte Région Centro (IT) Toscana Siena Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Contact administratif Laura Baldi (Dr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS Pays-Bas Contribution de l’UE € 640 980,00 Adresse PLESMANLAAN 121 1066 CX Amsterdam Voir sur la carte Région West-Nederland Noord-Holland Groot-Amsterdam Type d’activité Research Organisations Contact administratif Henri Van Luenen (Dr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée University of Zurich Suisse Contribution de l’UE € 569 244,00 Adresse RAMISTRASSE 71 8006 ZURICH Voir sur la carte Type d’activité Higher or Secondary Education Establishments Contact administratif Burkhard Becher (Dr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée